key: cord-0991038-puyfojgg
authors: Deniz, Melis; Tapısız, Anıl; Tezer, Hasan
title: Drugs being investigated for children with COVID‐19
date: 2020-06-07
journal: Acta Paediatr
DOI: 10.1111/apa.15399
sha: da33576bd53309deedbfc69d4e179c6d292b78b6
doc_id: 991038
cord_uid: puyfojgg

We were interested to read the review paper on COVID‐19 by Ludvigsson in Acta Paediatrica (1). The author mentioned that COVID‐19 appeared to be milder in children than in adults but said there was a knowledge gap about antiviral treatment in severely ill patients. We would like to provide some comments about the experimental drugs that are being considered to treat children with the disease.

We were interested to read the review paper on COVID-19 by Ludvigsson in Acta Paediatrica (1) . The author mentioned that COVID-19 appeared to be milder in children than in adults but said there was a knowledge gap about antiviral treatment in severely ill patients. We would like to provide some comments about the experimental drugs that are being considered to treat children with the disease.

Although the course of COVID-19 is milder in children, the use of experimental drugs for severely ill patients is still being debated. Remdesivir, which has shown promise in treating COVID-19 in adults, is a nucleotide analogue that inhibits viral ribonucleic acid (RNA) polymerase. The effectiveness of the drug was shown during the outbreaks of Ebola, severe acute respiratory syndrome coronavirus (SARS) and Middle-East syndrome related coronavirus (MERS). It has also been shown to be effective in vitro against SARS-CoV-2, which is the virus that causes COVID-19 (2) . Despite the absence of data on children with COVID-19, no adverse effects were observed when a baby who was diagnosed with Ebola was followed up after being treated with Favipiravir, which is an RNA-dependent RNA polymerase inhibitor, is another drug that is being assessed as a potential treatment for COVID-19. It was effective during the 2014-2016 Ebola outbreak and the 2009 influenza outbreak. When it was tested on COVID-19 patients above 16

years of age, it demonstrated faster viral clearance and higher recovery rates than lopinavir and ritonavir (7) . The treatment options for children were reviewed as soon as COVID-19 emerged, as the case fatality rate had been high in children during the Ebola outbreak. The paediatric use of Accepted Article

Systematic Review of COVID-19 in Children Shows Milder Cases and a Better Prognosis Than Adults

Compassionate Use of Remdesivir for Patients with Severe Covid-19

First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease

Deliberations on design options for randomized controlled clinical trials to assess the safety and efficacy of investigational therapeutics for the treatment of patients with Ebola virus disease

Remdesivir letter of Emergency Use Authorization

2020. Identifier: NCT04292899, Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering (Beijing)

Favipiravir for children with Ebola

Accepted Article